DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

Information source: Santen Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: 1.5% levofloxacin ophthalmic solution (Drug); 0.5% moxifloxacin hydrochloride ophthalmic solution (Drug); 0.3% gatifloxacin ophthalmic solution (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Santen Inc.


The primary objective of this study is to compare the concentration in human tears of levofloxacin and the active comparators at 15 minutes, 2,6, 12, and 24 hours after instillation of a single drop of medication.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science

Primary outcome: Concentration of levofloxacin, moxifloxacin or gatifloxacin in tears


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Be willing and able to provide written informed consent and HIPAA indicating that

they understand the purpose of and procedures required for the study and are willing to participate in the study

- Be willing and able to follow all instructions and attend all study visits

- If female and of childbearing potential, not be pregnant, nursing or planning a

pregnancy and agree to submit to a pregnancy test. The result of the test must be negative and female subjects of childbearing potential must also agree to use an acceptable method of contraception for the duration of the study (acceptable method of contraception includes oral, implantable, transdermal, or injectible contraceptives, spermicide with barrier, IUD, or surgical sterilization of partner) Exclusion Criteria:

- Have a known allergy and/or sensitivity to the test article(s) or its components or

any therapies associated with the study

- Have active signs or symptoms of any clinically significant ocular disorder (other

than refractive disorders)

- Have a history of dry eye syndrome

- Use disallowed medications (systemic or topical) (i. e. any fluoroquinolone

anti-infective agents or any topical ophthalmic products) during the appropriate pre-study washout period and during the study.

- Be a contact lens wearer who is unwilling to forego contact lens wear within 3 days

prior to the start of the study and for the duration of the study

- Have had any ocular surgical intervention 12 months prior to the study or anticipate

having ocular surgery during the study

- Be pregnant or nursing women; or women who have a positive urine pregnancy test at

screening or women of childbearing potential who refuse to use an adequate hormonal or mechanical means of birth control

- Be concurrently enrolled in an investigational drug or device study or have used an

investigational drug or device within 30 days of entry into this study

- Employees of the investigator or study center, with direct involvement in th proposed

study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

Locations and Contacts

Vistakon, Jacksonville, Florida 32256, United States
Additional Information

Starting date: May 2008
Last updated: February 4, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017